Joshua Liberman, MD
Cardiovascular Disease · Mequon, WINPI 1265551196
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $193,934 of the $230,074 with a category attached, or 84.3%. 28 manufacturers reported payments, led by Boehringer Ingelheim at 25.9% of the total. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $644.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$60K
- Esperion Therapeutics, Inc.$33K
- Boston Scientific$33K
- Lilly USA, LLC$23K
- Sanofi-aventis U.S. LLC$23K
- Alnylam Pharmaceuticals Inc.$20K
- plus $38K from 22 others
Across 2 payments — averaging $120.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$120
- Chiesi USA, Inc.$120
What the payments were for
- Consulting fees$13,7436%
- Speaking & faculty fees$193,93484%
- Travel & lodging$12,3875%
- Food & beverage$9,9944%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 70 | $59,602 |
| Esperion Therapeutics, Inc. | 35 | $33,436 |
| Boston Scientific | 26 | $33,243 |
| Lilly USA, LLC | 22 | $23,246 |
| Sanofi-aventis U.S. LLC | 19 | $22,679 |
| Alnylam Pharmaceuticals Inc. | 31 | $20,172 |
| AstraZeneca | 34 | $11,090 |
| Regeneron | 11 | $8,009 |
| Amarin Pharma, Inc. | 10 | $7,533 |
| Novo Nordisk | 9 | $2,870 |
| Akcea Therapeutics, Inc. | 9 | $2,589 |
| Abbott | 16 | $2,092 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,169 |
| Edwards Lifesciences | 4 | $465 |
| E.r. Squibb & Sons, L.L.C. | 11 | $324 |
| Chiesi USA, Inc. | 2 | $323 |
| Novartis | 15 | $247 |
| Vifor Pharma, Inc. | 1 | $200 |
| Abiomed | 1 | $158 |
| Amgen | 8 | $142 |
| Silk Road Medical, Inc. | 1 | $129 |
| Pfizer | 6 | $115 |
| Lexicon Pharmaceuticals, Inc. | 5 | $100 |
| Heartflow, Inc. | 3 | $69 |
| Itamar Medical Inc | 2 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$81,691
- NEXLIZET$33,000
- NEXLETOL$33,000
- WATCHMAN Access System$32,366
- PRALUENT$26,853
- AMVUTTRA$19,360
- FARXIGA$10,457
- Vascepa$7,355
- DISEASE STATE$4,048
- Ozempic$2,625
- TEGSEDI$2,189
- Mitra Clip system$1,804
- MULTAQ$450
- WATCHMAN FLX$319
- JUXTAPID$300
- Edwards SAPIEN 3 Transcatheter Heart Valve$283
- ONPATTRO$232
- Veltassa$200
- Impella$158
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$138
How this compares
$230,074 in reported general payments places this provider in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 43 | $1,037,481 |
| EliquisApixaban | 203 | $240,794 |
| Repatha SureclickEvolocumab | 121 | $115,866 |
| JardianceEmpagliflozin | 93 | $104,023 |
| XareltoRivaroxaban | 45 | $52,229 |
| EntrestoSacubitril/Valsartan | 36 | $44,307 |
| FarxigaDapagliflozin Propanediol | 40 | $36,315 |
| WegovySemaglutide | 20 | $27,496 |
| MounjaroTirzepatide | 24 | $27,425 |
| Praluent PenAlirocumab | 22 | $26,427 |
| MultaqDronedarone Hcl | 20 | $14,802 |
| VascepaIcosapent Ethyl | 35 | $12,829 |
| BystolicNebivolol Hcl | 11 | $7,652 |
| Colchicine | 109 | $5,778 |
| LivaloPitavastatin Calcium | 16 | $5,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $115 | $1,278,274246 claims |
| Boehringer IngelheimJardiance | $59,602 | $104,02393 claims |
| Johnson & JohnsonXarelto | $12 | $52,22945 claims |
| NovartisEntresto | $247 | $44,30736 claims |
| AstraZenecaFarxiga, Crestor | $11,090 | $39,55252 claims |
| Novo NordiskWegovy | $2,870 | $27,49620 claims |
| Lilly USA, LLCMounjaro | $23,246 | $27,42524 claims |
| Sanofi-aventis U.S. LLCMultaq | $22,679 | $14,80220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Mequon
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Tadeo Diaz BalderramaFond du Lac$72K
- David Luddenla Crosse$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.